Back to News
Market Impact: 0.15
Nuritas Appoints Former Unilever North America President Kees Kruythoff as Board Chair
Source: PR Newswire
Healthcare & BiotechManagement & Governance
Nuritas appointed Kees Kruythoff, a 30-year industry veteran with global scaling and commercialization experience, as chair of its board. The leadership appointment supports the bioactive peptide discovery company's commercialization and growth ambitions, though the announcement provides no financial targets or operating metrics.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.25
More News
- Biotech stocks are surging. How investors can play the new drug innovation boom
- IMDELLTRA® IN COMBINATION WITH IMFINZI® REDUCED RISK OF DEATH BY AN UNPRECEDENTED 58% IN FIRST-LINE EXTENSIVE STAGE SMALL CELL LUNG CANCER
- ‘There’s nothing temporary about a temporary store’: How Spirit Halloween’s CEO took it from 130 stores to 1,550—and swallowed your mall’s Hot Topic
- Thousands of Israelis rally against Netanyahu gov’t days before election
- J&J prostate cancer drug shows promising tumor responses in early trial
- Pfizer reports phase 2 data for 25-valent pneumococcal vaccine
From AllMind Research
- Anthropic IPO Preview: Valuation, Timing, and What to Watch
- Shein After the IPO: Venue, Valuation, and What Must Be Proved
- What AI Research Tools Should a Small Hedge Fund Buy First?
- AlphaSense Pricing: What Public Contract Data Shows in 2026
- Eli Lilly Q4 2025 Earnings: Revenue Surges 43% as Mounjaro and Zepbound Dominate the GLP-1 Market